Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 4/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519677 | 1.00 | ESR1 (0.56) | ESR1LMNAPOLBMEN1GAA | |
| SCHEMBL644486 | 0.89 | ALDH1A1 (0.52) | LMNAPOLBMEN1GAAMAPT | |
| SCHEMBL3588564 | 0.87 | LMNA (0.47) | ESR1LMNAPOLBMEN1GAA | |
| SCHEMBL4843221 | 0.86 | MMP8 (0.52) | LMNAPOLBMEN1GAAMAPT | |
| SCHEMBL926563 | 0.85 | NPSR1 (0.48) | ESR1LMNAPOLBMEN1GAA | |
| SCHEMBL2519245 | 0.85 | ALDH1A1 (0.53) | MEN1MAPK1KMT2AALDH1A1NPSR1 | |
| SCHEMBL2519247 | 0.85 | ALDH1A1 (0.53) | MEN1MAPK1KMT2AALDH1A1NPSR1 | |
| SCHEMBL927698 | 0.85 | ESR1 (0.57) | ESR1LMNAPOLBALDH1A1NPSR1 | |
| SCHEMBL644139 | 0.84 | ALDH1A1 (0.47) | LMNAPOLBMEN1GAAMAPT | |
| SCHEMBL5847318 | 0.82 | DRD2 (0.45) | LMNAPOLBMEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | disclosed |
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2009-05-07 | — | — | US | disclosed |
| EP-1448523-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | disclosed |
| US-7183304-B2 | such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents | NOVARTIS AG (CH) | 2007-02-27 | — | — | US | disclosed |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | BACH ANDREW THOMAS (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1448523-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Novartis AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043985-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | ESR1 1094/4885LMNA 3283/4885POLB 1540/4885 |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | PPARG, GPR119, PPARD | ESR1 1073/4885LMNA 3196/4885POLB 1810/4885 |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | ESR1 1094/4885LMNA 3283/4885POLB 1540/4885 |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | ESR1 1094/4885LMNA 3283/4885POLB 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.